Compare SHIM & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | VANI |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 111.0M |
| IPO Year | 2023 | 2014 |
| Metric | SHIM | VANI |
|---|---|---|
| Price | $2.52 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $3.83 |
| AVG Volume (30 Days) | 130.1K | ★ 153.0K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | $4,000,000.00 |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.95 | $0.92 |
| 52 Week High | $6.76 | $1.92 |
| Indicator | SHIM | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 28.76 | 36.32 |
| Support Level | $2.45 | $1.15 |
| Resistance Level | $4.09 | $1.25 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 10.81 | 2.70 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.